Redhill Biopharma Ltd - Asset Resilience Ratio
Redhill Biopharma Ltd (RDHL) has an Asset Resilience Ratio of 14.88% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Redhill Biopharma Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Redhill Biopharma Ltd's Asset Resilience Ratio has changed over time. See Redhill Biopharma Ltd (RDHL) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Redhill Biopharma Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see RDHL market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.73 Million | 14.88% |
| Total Liquid Assets | $2.73 Million | 14.88% |
Asset Resilience Insights
- Moderate Liquidity: Redhill Biopharma Ltd has 14.88% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Redhill Biopharma Ltd Industry Peers by Asset Resilience Ratio
Compare Redhill Biopharma Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Redhill Biopharma Ltd (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Redhill Biopharma Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.16% | $2.73 Million | $18.04 Million | +11.73pp |
| 2023-12-31 | 3.43% | $790.04K | $23.05 Million | +3.42pp |
| 2022-12-31 | 0.01% | $15.00K | $158.87 Million | -4.70pp |
| 2021-12-31 | 4.71% | $8.53 Million | $181.19 Million | +4.43pp |
| 2020-12-31 | 0.28% | $498.00K | $180.24 Million | -25.16pp |
| 2019-12-31 | 25.44% | $18.85 Million | $74.10 Million | -13.31pp |
| 2018-12-31 | 38.74% | $24.18 Million | $62.41 Million | -13.14pp |
| 2017-12-31 | 51.88% | $29.75 Million | $57.34 Million | +35.22pp |
| 2016-12-31 | 16.67% | $12.37 Million | $74.21 Million | -38.13pp |
| 2015-12-31 | 54.80% | $36.62 Million | $66.83 Million | -4.30pp |
| 2014-12-31 | 59.10% | $17.05 Million | $28.86 Million | +57.27pp |
| 2013-12-31 | 1.83% | $262.00K | $14.34 Million | -5.89pp |
| 2012-12-31 | 7.72% | $1.55 Million | $20.10 Million | -14.96pp |
| 2011-12-31 | 22.67% | $4.58 Million | $20.19 Million | +22.53pp |
| 2010-12-31 | 0.14% | $15.00K | $10.51 Million | -- |
About Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for … Read more